Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Triamcinolone Acetonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 6/20 | 0.89 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.89 |
| ▸ | LMNA | P02545 | 6/20 | 0.89 |
| ▸ | PGR | P06401 | 6/20 | 0.89 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.89 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.79 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.79 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.79 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.79 |
| ▸ | BLM | P54132 | 1/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.79 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.71 |
| ▸ | AR | P10275 | 3/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | APEX1 | P27695 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triamcinolone Acetonide SCHEMBL1561091 | 1.00 | HIF1A (0.89) | HIF1ACYP3A4LMNANR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL8780600 | 0.98 | HIF1A (0.87) | HIF1ACYP3A4LMNANR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL4002585 | 0.94 | HIF1A (1.00) | HIF1ACYP3A4LMNANR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL11911289 | 0.94 | HIF1A (1.00) | HIF1ACYP3A4LMNANR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL1692059 | 0.94 | HIF1A (1.00) | HIF1ACYP3A4LMNANR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL1639690 | 0.94 | HIF1A (1.00) | HIF1ACYP3A4LMNANR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL13839748 | 0.94 | HIF1A (1.00) | HIF1ACYP3A4LMNANR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL16393966 | 0.94 | HIF1A (1.00) | HIF1ACYP3A4LMNANR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL21051778 | 0.94 | HIF1A (1.00) | HIF1ACYP3A4LMNANR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL4448 | 0.94 | HIF1A (1.00) | HIF1ACYP3A4LMNANR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101420977-A | NOGO receptor antagonists | BIOGEN IDEC INC (US) | 2009-04-29 | — | — | CN | claimed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| EP-0579760-A4 | METHOD OF TREATMENT USING STEROID MOUTHWASH. | EISEN DRORE (US) | 1995-07-05 | — | — | EP | claimed |
| EP-0579760-A1 | METHOD OF TREATMENT USING STEROID MOUTHWASH | Eisen, Drore (US) | 1994-01-26 | — | — | EP | claimed |
| WO-1992018133-A1 | METHOD OF TREATMENT USING STEROID MOUTHWASH | EISEN DRORE (US) | 1992-10-29 | — | — | WO | claimed |
| US-20240165130-A1 | COMPOSITE DRUG PARTICLES AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-05-23 | — | — | US | disclosed |
| CN-117500823-A | Chimeric proteins in autoimmunity | 沙塔克实验室有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-110658337-B | Diagnosis and treatment of autoimmune diseases | 武田药品工业株式会社 | 2023-06-16 | — | — | CN | disclosed |
| US-10584181-B2 | Methods of making and using multispecific antibody panels and antibody analog panels | GENENTECH, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| CN-101420977-B | Nogo receptor antagonists | 比奥根MA公司 | 2016-08-10 | — | — | CN | disclosed |
| EP-1455756-B2 | PHARMACEUTICAL NANOPARTICULATE COMPOSITION OF A TACHYKININ RECEPTOR ANTAGONIST | MERCK SHARP & DOHME (US) | 2015-09-23 | — | — | EP | disclosed |
| EP-1455756-B1 | PHARMACEUTICAL NANOPARTICULATE COMPOSITION OF A TACHYKININ RECEPTOR ANTAGONIST | MERCK & CO INC (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007096782-A2 | COMPOSITIONS FOR DISORDERS ASSOCIATED WTTH METACHROMATIC CELL ACTIVATION | VALORISATION RECHERCHE HSCM, LIMITED PARTNERSHIP (CA) | 2007-08-30 | — | — | WO | disclosed |
| US-20070197491-A1 | Method for treating primary and secondary forms of glaucoma | ALCON, INC. (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007041593-A2 | ANTI-SCARRING DRUG COMBINATIONS AND USE THEREOF | COMBINATORX, INCORPORATED (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2005110367-A2 | SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND METHODS FOR PREVENTING RETINAL DYSFUNCTION | ALLERGAN, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050244506-A1 | Sustained release intraocular implants and methods for preventing retinal dysfunction | ALLERGAN, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2004023984-A2 | NOVEL COMPOSITION AND METHOD FOR TREATMENT OF UPPER RESPIRATORY CONDITIONS | SMITH C STEVEN (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240165130-A1 | COMPOSITE DRUG PARTICLES AND USES THEREOF | LIPC, LIPA, FABP4 | NR3C1 108/4885HIF1A 4001/4885CYP3A4 193/4885 |
| US-10584181-B2 | Methods of making and using multispecific antibody panels and antibody analog panels | FCGR2A, FCGR3B, FCGR1A | NR3C1 1811/4885HIF1A 4674/4885CYP3A4 1650/4885 |
| US-20050244506-A1 | Sustained release intraocular implants and methods for preventing retinal dysfunction | ADRB2, ADRA2A, ADRA2B | NR3C1 196/4885HIF1A 418/4885CYP3A4 3524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.